Raising awareness on the involvement of primary care providers can assist cancer survivors in transitioning from oncology care, said Kelly Filchner, MSN, director at Fox Chase Cancer Center Partners.
Raising awareness on the involvement of primary care providers can assist cancer survivors in transitioning from oncology care, said Kelly Filchner, MSN, director at Fox Chase Cancer Center Partners.
Transcript
Are there challenges with getting patients to make the transition to their primary care provider (PCP)?
Educating patients from the beginning that their PCP is part of it, they get a little scared. You're going through cancer care, and you're followed so closely for perhaps a year at a time, maybe more than a year, depending on what your treatment is. Then all of a sudden, it's like, okay, you're a survivor, and now you're going to go do this, and it kind of scares people. So, we just need to make sure that they know that the PCP has been involved from the beginning. They know what's going on, and this is what we're going to do in oncology—we're going to take care of your side effects that you still might have, and we're going to make sure you're getting your CAT scans or whatever you need to follow your cancer, but your PCP is going to take care of making sure that even if you're a woman and you had a breast cancer, that you're still going for your colonoscopy, and other screening measures, as well as, taking care of exercise and obesity if that's an issue for that patient, along with their other comorbid conditions.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More